1. Repositório Institucional - Universidade Federal de Uberlândia
2. Instituto de Ciências Biomédicas (ICBIM)
3. TCC - Ciências Biomédicas

ORCID:	http://orcid.org/0009-0001-6214-2632
Tipo de documento:	Trabalho de Conclusão de Curso
Tipo de acceso:	Acesso Embargado
Fecha de embargo:	2027-06-25
Título:	Combatendo o vírus Zika com um complexo de cobalto(II) e uma base de Schiff derivada da amantadina: uma nova estratégia para o desenvolvimento de fármacos antivirais
Título (s) alternativo (s):	Targeting Zika virus with a cobalt(II) complex and a Schiff base derived from amantadine: a new strategy for antiviral drug development
Autor:	d'Almeida, Júlia Amaral Vieira
Primer orientador:	Jardim, Ana Carolina Gomes
Primer coorientador:	Cassani, Natasha Marques
Primer miembro de la banca:	Calmon, Marillia de Freitas
Segundo miembro de la banca:	Souza, Eliza Flores de
Resumen:	Zika fever is a disease caused by the Orthoflavivirus zikaense (Zika virus, ZIKV), mainly transmitted by mosquitoes from the genus Aedes. It has been previously associated with cases of microcephaly and Guillain-Barré syndrome, drawing the attention of the health authorities worldwide. However, there are no vaccines and antivirals available against ZIKV, and therefore, the search for compounds with antiviral activity is mandatory. In this context, metallodrugs have demonstrated antiviral activity against several viruses. Here we demonstrated the anti-ZIKV activity of the cobalt ion (Co) coordinated to a Schiff base derived from amantadine using salicylaldehyde (atdSali), a complex named Co-atdSali, compared to the antiviral activity of its ligands. Vero E6 cells were infected with ZIKVPE243 in the presence of compounds at non-cytotoxic concentrations for 72 hours, when virus titers were evaluated, through immunofluorescence, and cytotoxicity, through MTT assay. Results demonstrated a strong anti-ZIKV activity, with Co-atdSali reducing over 91% of ZIKV infection, whereas Co(II) and atdSali reduced 44 and 8% of ZIKV replication, respectively. Moreover, the complex presented strong dose-response inhibition of ZIKV replication, with a SI of 14.7, when compared to its ligands, Co(II) and atdSali, that presented a SI of 3.9 and 1.6, respectively. Our findings show that the coordination of Co(II) to the atdSali ligand leads to a complex with enhanced antiviral activity when compared to the free ligands indicating its usage as a template for the development of future antiviral candidate drugs against Zika fever.
Palabras clave:	Antivirais Zika virus Complexo metálico Cobalto Antiviral drugs Metallic complex Cobalt
Área (s) del CNPq:	CNPQ::CIENCIAS DA SAUDE CNPQ::CIENCIAS BIOLOGICAS::MICROBIOLOGIA
Idioma:	eng
País:	Brasil
Editora:	Universidade Federal de Uberlândia
Cita:	D'ALMEIDA, Júlia A. V. Combatendo o vírus Zika com um complexo de cobalto(II) e uma base de Schiff derivada da amantadina: uma nova estratégia para o desenvolvimento de fármacos antivirais. 2025. 23 f. Trabalho de Conclusão de Curso (Graduação em Biomedicina) – Universidade Federal de Uberlândia, Uberlândia, 2025.
URI:	https://repositorio.ufu.br/handle/123456789/46209
Fecha de defensa:	29-abr-2025
Aparece en las colecciones:	TCC - Ciências Biomédicas

Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.